Key points are not available for this paper at this time.
In this first placebo-controlled trial in patients with Eisenmenger syndrome, bosentan was well tolerated and improved exercise capacity and hemodynamics without compromising peripheral oxygen saturation.
Galiè et al. (Mon,) studied this question.